SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven shines on securing one Product Patent each in Mexico and Singapore

22 May 2015 Evaluate

Suven Life Sciences is currently trading at Rs. 316.85, up by 5.90 points or 1.90% from its previous closing of Rs. 310.95 on the BSE.

The scrip opened at Rs. 310.30 and has touched a high and low of Rs. 319.45 and Rs. 309.00 respectively. So far 91952 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 338.50 on 15-Apr-2015 and a 52 week low of Rs. 82.70 on 26-May-2014.

Last one week high and low of the scrip stood at Rs. 323.70 and Rs. 301.10 respectively. The current market cap of the company is Rs. 4003.03 crore.

The promoters holding in the company stood at 59.44% while Institutions and Non-Institutions held 8.36% and 32.20% respectively.

Suven Life Sciences has been granted one product patent from Mexico and one product patent from Singapore corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029. The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).

With these new patents, the company has a total of eighteen granted patents from Mexico and twenty granted patents from Singapore. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.

 

Suven Life Sciences Share Price

215.50 19.60 (10.01%)
20-Apr-2026 11:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.50
Dr. Reddys Lab 1237.75
Cipla 1238.15
Zydus Lifesciences 941.45
Lupin 2330.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×